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346Cardiac troponin can be mea-
sured with high-sensitivity tro-
ponin assays in many individuals
who are clinically well (1–3). In
a recent large community-based
study, detectable levels of hsTnT
>0.003 ng/ml were found in 25%
of the population and were asso-
ciated with an increased risk of all-
cause mortality (1). In patients
with stable coronary heart disease
(CHD) and preserved left ven-
tricular ejection fraction, hsTnT
levels were detected in 98% of
patients, and higher levels werepredictive of cardiovascular death and heart failure (4).page 355No studies have assessed change in troponin levels for
prediction of outcomes in a broad population of patients
with CHD who are clinically stable following myocardial
infarction (MI) or unstable angina. We therefore measured
troponin I (TnI) levels using a contemporary sensitive assay
(5) at baseline and their change at 1 year in patients in the
large LIPID (Long-Term Intervention with Pravastatin in
Ischaemic Disease) study and evaluated their relationship to
outcomes over long-term follow-up (6).
Methods
Study population. The design of the LIPID study has
been described in detail previously (7). Patients 31 to 75
years of age, with an MI or hospital admission for unstable
angina 3 to 36 months previously, entered the LIPID study
if their plasma total cholesterol was 4.0 to 7.0 mmol/l (155
to 271 mg/dl) and fasting triglycerides <5.0 mmol/l
(<445 mg/dl). Patients with heart failure were excluded.
After an 8-week single-blind placebo run-in phase, 9,014
patients were randomly allocated to receive pravastatin 40
mg daily or matching placebo. Both groups continued to
receive dietary advice. The median follow-up was 6 years.
All deaths, MIs, and strokes were reviewed by blinded
outcome assessment committees. MI was deﬁned as deﬁnite
development of new pathological Q waves of at least 0.03 s
in at least 2 electrocardiogram leads or 2 of the following:
1) history of typical ischemic pain lasting for 15 min and
unresponsive to sublingual nitrates; 2) elevation of creatine
kinase-MB >2 times the upper limit of normal; and
3) evolution of ST-T changes.lheim, Siemens, and Abbott Diagnostics; and
hringer Ingelheim, Bayer, and Thermo Fisher.
t they have no relationships relevant to the
3; revised manuscript received July 19, 2013,Laboratory methods. Blood was drawn after a 12-h fast
into EDTA tubes. Samples were stored in at least 70C
freezers until analysis. TnI was measured at randomization
and at 1 year by the Siemens cTnI-Ultra assay (Erlangen,
Germany), which is a contemporary sensitive assay (5). The
assay has a limit of detection of 0.006 ng/ml, with a 99th
percentile of 0.04 ng/ml for a normal reference population
and a 10% coefﬁcient of variation of 0.03 ng/ml (8) and 20%
coefﬁcient of variation of 0.17 ng/ml (9).
Statistical methods. All analyses were pre-speciﬁed in
a biomarker protocol with the composite of CHD death and
nonfatal MI (CHD events) as the primary endpoint. Other
endpoints were expanded composites of major cardiovascular
disease (CVD) events (CVD death, nonfatal MI, and stroke)
and total CVD events (major CVD events, unstable angina,
and revascularization), MI (both fatal and nonfatal), stroke,
hospitalization for heart failure, coronary death, CVD death,
and total mortality. It was pre-speciﬁed in our statistical
analysis plan that all continuous variables were to be modeled
using categories due to the skewed nature of most of these
predictors. Estimated glomerular ﬁltration rate and systolic
blood pressure were analyzed in quartiles. Age was analyzed in
4 groups:<55, 55 to 64, 65 to 69, and70 years. The data for
TnI was split into approximate tertiles, with the cut points
below the detection limit of 0.006 ng/ml (38%), 0.006
to <0.018 ng/ml (31%), and 0.018 ng/ml (31%). Change
was deﬁned as moving up or down one category. Change
of 50% or <50% was also evaluated. Tests of trend over
categories were performed using either logistic regression or
ordinal logistic regression analyses as appropriate; for
continuous data, the test for trend was performed using
a linear model. The effects of pravastatin on change in TnI
were examined with the Wilcoxon rank sum test.
The relationship between TnI and outcomes was assessed
using a pre-speciﬁed time-to-event model adjusted for sex,
treatment, prior stroke, diabetes mellitus, current smoking,
hypertension, fasting glucose, total cholesterol, apolipopro-
teinB (ApoB), ApoA1, high-density lipoprotein cholesterol,
triglycerides, age, nature of qualifying prior acute coronary
syndromes (ACS), timing of coronary revascularization,
systolic blood pressure, atrial ﬁbrillation, estimated glomer-
ular ﬁltration rate, body mass index, dyspnea class, angina
grade, white blood cell count, peripheral vascular disease, and
use of aspirin at baseline. Each of these variables had been
shown to be independent predictors of CVD events in risk
models in the LIPID study (10–12). The relationship
between change in TnI and subsequent events was assessed in
a landmark analysis of 6,084 patients alive at 1 year who had
not had an MI, stroke, revascularization, or unstable angina.
An additional analysis including all patients regardless of
revascularization, admission to hospital with unstable angina,
or stroke was also performed. These analyses were adjusted for
the above covariates as well as baseline TnI levels. A further
analysis of main results was undertaken, with adjustment for 2
additional biomarkers separately: high-sensitivity C-reactive
protein (hsCRP) and B-type natriuretic peptide (BNP).
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347Discrimination of each risk model was assessed using the
C-statistic, integrated discrimination index, and net reclas-
siﬁcation improvement index (NRI). The NRI was calcu-
lated using event probabilities of 7.5%, 7.5% to 10%,
>10% to 15%, and >15% for the primary outcome of CHD
events. The LIPID study was a secondary prevention study
and because there are no clinically meaningful categories
published, we based our categories on pre-speciﬁed quartiles
for CHD events. Because NRIs are not transferable from one
setting to another, we have provided the relative NRIs of
different factors in a multivariate model of interest. Patients
changed classiﬁcation if they moved between these categories
in the 2 models with and without TnI. The base model
included all risk factors stated earlier (including treatment),
except for ApoA1 and ApoB. NRI was also calculated
for change in TnI, when the base model included all risk
factors in the previous model, as well as baseline TnI (13).
Results
Online Figure 1 shows the disposition of the patients. TnI
was measured at baseline in 87% of patients. The patients
who did not have TnI measurements were slightly younger
and more likely to be smokers and not on aspirin. Other-
wise, they were similar to those who had baseline biomarker
measurements.
Baseline troponin levels. Table 1 shows the baseline
characteristics of patients according to approximate tertiles
of TnI. Patients in the highest tertiles of TnI levels were
more likely to be older, have diabetes, have atrial ﬁbrillation,
have a history of hypertension or previous MI, and be taking
angiotensin-converting enzyme inhibitors and were less
likely to be on beta-blockers. Higher TnI levels were related
to increased levels of BNP and hsCRP and increased LIPID
risk score (10).
Baseline TnI levels were strongly related to the primary
outcome of CHD event death (p < 0.001), as well as other
CVD outcomes, including nonfatal MI, stroke, and heart
failure. Following adjustment for 23 other baseline risk
factors and treatment, TnI levels remained highly signiﬁcant
for these outcomes (all p < 0.001 except for stroke [p ¼
0.02]) and nonfatal MI (p ¼ 0.04) (Fig. 1). In an additional
analysis also adjusted for hsCRP and BNP levels, TnI
independently predicted subsequent CHD events, major
CVD events, total CVD events, MI, heart failure, and total
mortality (Online Fig. 2).
Levels of TnI >0.04 ng/ml (99th percentile) were found
in 8.4% of patients at baseline. Compared with undetectable
levels, TnI levels >0.04 ng/ml were associated with an
adjusted hazard ratio (HR) for CHD death or MI of 2.02
(95% CI: 1.66 to 2.45; p for trend < 0.001) and adjusted
HR of 2.22 for all-cause mortality (95% CI: 1.81 to 2.72;
p for trend <0.001).
Effect of pravastatin on troponin I levels. TnI levels were
modestly lower at 1 year in patients randomized to receive
pravastatin (median: 0.008 ng/ml [Q1 to Q3: 0.006 to0.018]) versus baseline (median: 0.010 ng/ml [Q1 to Q3:
0.006 to 0.021]; p < 0.001). There was no change in the
placebo group for TnI levels at 1 year (median: 0.009 ng/ml
[Q1 to Q3: 0.006 to 0.019]) versus baseline 0.010 ng/ml
(Q1 to Q3: 0.006 to 0.020; p ¼ 0.28). This small treatment
effect was statistically signiﬁcant (p ¼ 0.002) but did not
result in important differences in the proportion of patients
changing category (Tables 2 and 3).
The relative treatment effect of pravastatin was similar
across each baseline category of TnI levels for CHD death
and MI as well as other outcomes (Table 4). However,
higher baseline TnI levels were associated with a larger
absolute beneﬁt of pravastatin and therefore fewer numbers
needed to treat. For example, 37 patients would need to
be treated with pravastatin over 5 years to prevent 1
additional CVD death for those with a TnI 0.018 ng/ml
compared with 106 needed to treat for those with
a TnI <0.006 ng/ml.
Overall change in troponin levels. Levels of TnI between
baseline and 1 year decreased by one tertile category in
25.7%, increased in 23%, and were unchanged in 51.3% of
patients and were not different by treatment (Table 2). The
proportion of patients with a change in category was inde-
pendent of randomized treatment (27% vs. 25% decreased
category for pravastatin vs. placebo). Table 3 shows the
percentage of patients changing categories from baseline to 1
year according to which categories they were in at baseline.
If TnI levels moved to a higher category, the adjusted HR
for CHD events was 1.31 (95% CI: 1.06 to 1.62). The HR
associated with a shift from nondetectable to the middle
tertile compared with staying nondetectable was 1.34 (95%
CI: 1.00 to 1.81), and the HR associated with a shift from
the middle tertile to the highest tertile, compared with
staying in the middle tertile, was 1.57 (95% CI: 1.15 to
2.14); however, if TnI levels decreased, the HR decreased
(HR: 0.90; 95% CI: 0.74 to 1.09). The trend for a higher
rate of events, if TnI levels increased, remained highly
signiﬁcant after adjustment for all other baseline variables,
including baseline TnI category (p for trend ¼ 0.01) (Fig. 2).
An analysis containing both the baseline and 1-year TnI
levels (rather than change) demonstrated that both were
statistically signiﬁcant in the model (p < 0.001 and p ¼
0.01, respectively).
In an analysis that included all patients between baseline
and 1 year regardless of whether coronary revascularization,
hospitalization for unstable angina, or stroke occurred, the
results did not signiﬁcantly change (Online Fig. 3).
Increases in TnI levels were associated with higher
all-cause mortality (HR: 1.44; 95% CI: 1.16 to 1.79) and
decreases in TnI were associated with a lower mortality
(HR: 0.83; 95% CI: 0.68 to 1.02). Changes in TnI levels
also signiﬁcantly predicted the rate of major CVD events
(increase HR: 1.33; decrease HR: 0.88), total CVD events
(increaseHR: 1.21; decrease HR: 0.89), CVDdeath (increase
HR: 1.56; decrease HR: 0.77), and heart failure (increase
HR: 1.49; decrease HR: 0.83) (all p < 0.001 except heart
Table 1 Baseline Characteristics
Troponin < Detectable Range
<0.006 ng/ml
(n ¼ 2,967)
Troponin
0.006–<0.018 ng/ml
(n ¼ 2,436)
Troponin
0.018 ng/ml
(n ¼ 2,460) p Trend
Randomized to pravastatin 1,486 (50) 1,211 (50) 1,244 (51) 0.66
Troponin, ng/ml 0.006  0.000 0.012  0.003 0.048  0.097 <0.001
Age at randomization, yrs 61.0 (54.0–67.0) 62.0 (56.0–68.0) 64.0 (57.0–68.0) <0.001
Age 65 yrs 1,030 (35) 972 (40) 1,107 (45) <0.001
Female 538 (18) 407 (17) 388 (16) 0.03
Months from QE 14.5 (8.1–25.6) 13.9 (7.8–25.2) 13.3 (7.7–24.3) <0.01
Current smoker 285 (10) 218 (9) 232 (9) 0.96
Hypertension 1,159 (39) 1,054 (43) 1,078 (44) <0.01
Diabetes 229 (8) 200 (8) 247 (10) <0.01
Obese 521 (18) 412 (17) 464 (19) 0.14
Previous stroke 97 (3) 95 (4) 130 (5) <0.001
Systolic BP, mm Hg 133  19 135  20 135  20 0.02
Diastolic BP, mm Hg 80  11 81  11 80  11 0.68
Dyspnea NYHA class >I 266 (9) 217 (9) 278 (11) <0.01
Angina CCVS grade >0 1,123 (38) 880 (36) 924 (38) 0.96
Atrial ﬁbrillation 25 (1) 38 (2) 47 (2) <0.01
Total cholesterol, mmol/l 5.6  0.8 5.7  0.8 5.7  0.8 <0.001
LDL cholesterol, mmol/l 3.9  0.7 3.9  0.7 3.9  0.7 <0.001
HDL cholesterol, mmol/l 0.9  0.2 1.0  0.2 1.0  0.2 <0.001
Triglycerides, mmol/l 1.5 (1.2–2.1) 1.6 (1.2–2.2) 1.6 (1.2–2.2) <0.01
Total cholesterol:HDL cholesterol 6.2  1.5 6.2  1.5 6.2  1.6 0.75
eGFR, ml/min/1.73 m2 71 (61–82) 70 (61–80) 68 (58–78) <0.001
WBC count,  108 6.9 (5.9–8.1) 7.0 (6.0–8.2) 7.1 (6.1–8.3) <0.001
Previous coronary revascularization
No revascularization 1,706 (57) 1,466 (60) 1,438 (58) 0.78
PCI only 379 (13) 260 (11) 231 (9)
CABG only 776 (26) 644 (26) 721 (29)
PCI and CABG 106 (4) 66 (3) 70 (3)
No MI 1,256 (42) 851 (35) 736 (30) <0.001
Single MI 1,459 (49) 1,305 (54) 1,351 (55)
Multiple MIs 252 (8) 280 (11) 373 (15)
Medications
Aspirin 2,469 (83) 2,020 (83) 2,012 (82) 0.15
ACE inhibitors 331 (11) 384 (16) 539 (22) <0.001
Beta-blockers 1,418 (48) 1,199 (49) 1,074 (44) <0.001
Calcium antagonists 1,048 (35) 803 (33) 837 (34) 0.50
LIPID risk score (8) 5.4  3.3 5.9  3.5 6.3  3.7 <0.001
Baseline biomarker levels
BNP, pg/ml 18.6 (7.9–37.3) 23.3 (9.7–51.1) 31.7 (13.1–71.2) <0.001
hsCRP, mg/l 2.3 (1.2–4.6) 2.4 (1.2–4.6) 2.7 (1.3–5.2) 0.13
Values are n (%), mean  SD, or median (interquartile range).
ACE ¼ angiotensin-converting enzyme; BNP ¼ B-type natriuretic peptide; BP ¼ blood pressure; CABG ¼ coronary artery bypass graft; CCVS ¼ Canadian Cardiovascular
Society; eGFR ¼ estimated glomerular ﬁltration rate; HDL ¼ high-density lipoprotein; hsCRP ¼ high-sensitivity C-reactive protein; IQR ¼ interquartile range;
LDL ¼ low-density-lipoprotein; LIPID ¼ Long-Term Intervention With Pravastatin in Ischaemic Disease; MI ¼ myocardial infarction; NYHA ¼ New York Heart Association;
PCI ¼ percutaneous coronary intervention; QE ¼ qualifying event; WBC ¼ white blood cell.
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348failure [p ¼ 0.002]). Changes in TnI levels were not so
signiﬁcantly associated with MI or stroke (p ¼ 0.07).
The effect of pravastatin onCVDevent reduction remained
essentially unchanged after adjustment for change in TnI
levels. For example, pravastatin reduced the number of CHD
events by 24% (HR: 0.76; p < 0.001), major CVD events by
25% (HR: 0.75; p < 0.001), total CVD events by 21% (HR:
0.79; p < 0.001), and all-cause mortality by 25% (HR: 0.75;
p < 0.001) after adjustment for baseline risk factors, baseline
TnI levels, and change in baseline TnI category.On multivariate analysis, with the addition of baseline
hsCRP and change, change in TnI level remained an
independent predictor for all of the above mentioned
outcomes (each p < 0.003 except for CHD events [p ¼
0.02]). When baseline BNP and change were added to the
23 baseline risk factors, change in TnI level remained
signiﬁcant for all endpoints (p < 0.008) except for CHD
events (p ¼ 0.05).
Findings were similar when a 50% change was used
rather than tertile category as the criterion for change except
Figure 1 Forest Plots Showing Outcomes Related to Baseline Troponin I Levels Adjusted for 23 Baseline Variables and Treatment
Hazard ratios (HRs) were compared with not detectable troponin I (TnI) group. *p value for trend. yHRs and 95% CI were adjusted for baseline variables: treatment, sex, stroke,
diabetes, smoking, hypertension, total cholesterol, apolipoprotein B (ApoB), ApoA1, high-density lipoprotein cholesterol, age, nature of prior acute coronary syndrome, timing of
coronary revascularization, systolic blood pressure, atrial ﬁbrillation, estimated glomerular ﬁltration rate, body mass index, dyspnea class, angina grade, white blood cell count,
peripheral vascular disease, triglycerides, fasting glucose, and aspirin at baseline. CHD ¼ coronary heart disease; CVD ¼ cardiovascular disease; MI ¼ myocardial infarction.
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349that to change independently predicted stroke (p ¼ 0.02)
(Fig. 3). No factors were identiﬁed that predicted either an
increase or decrease in TnI levels. Online Figure 4 shows
the results for a 50% change for all patients, including those
who had an event between baseline and 1 year. No factors
were identiﬁed that predicted either an increase or decrease
in TnI levels.Table 2 Change in Troponin I Levels From Baseline to Year 1*
Placebo
(n ¼ 3,036)
Pravastatin
(n ¼ 3,048)
Lower 750 (24.7%) 815 (26.7%)
Same 1,564 (51.5%) 1,556 (51.1%)
Higher 722 (23.8%) 677 (22.2%)
Values are n (%). *p ¼ 0.19: changes are recorded as either in the same category (not detectable,
0.006 to <0.018, or 0.018) or in a lower or higher category compared with baseline.NRI, C-statistic, and integrated discrimination index.
Table 5 shows the baseline and landmark reclassiﬁcations for
CHD death and MI and for mortality. For mortality, the
baseline model improved classiﬁcation by 4.8% and the
landmark model by 1.4% with the C-statistic changing from
0.665 to 0.673 for the baseline model and from 0.675 to
0.677 for the landmark model.Table 3
Overall Change in Troponin I Levels From
Baseline to Year 1
Troponin Levels at Year 1
Not
Detectable 0.006–<0.018 ng/ml 0.018 ng/ml
Not detectable 62.1% 23.8% 14.1%
0.006–<0.018 ng/ml 35.3% 36.3% 28.4%
0.018 ng/ml 20.0% 27.5% 52.5%
Table 4 Effect of Pravastatin Treatment on Clinical Events by Baseline Troponin I Category
Endpoint TnI Level, ng/ml
Placebo,
5-yr rate %
Pravastatin,
5-yr rate %
Hazard Ratio
(95% CI)* NNT
CHD events (CHD death or nonfatal MI) <0.006
0.006–<0.018
0.018
9.3
12.6
17.4
7.3
10.0
15.1
0.73 (0.58–0.92)
0.75 (0.60–0.93)
0.85 (0.71–1.02)
52
39
29
Major CVD events (CVD death,
nonfatal MI, or stroke)
<0.006
0.006–<0.018
0.018
12.1
15.7
21.7
9.3
13.0
18.0
0.74 (0.61–0.90)
0.77 (0.63–0.93)
0.81 (0.69–0.95)
39
31
23
Total CVD events (major CVD, unstable
angina, or revascularization)
<0.006
0.006–<0.018
0.018
31.6
35.5
41.4
28.4
31.3
36.4
0.87 (0.77–0.98)
0.85 (0.75–0.97)
0.83 (0.74–0.94)
26
24
21
CVD death <0.006
0.006–<0.018
0.018
4.0
7.5
11.9
3.3
5.7
9.7
0.72 (0.52–0.99)
0.70 (0.53–0.93)
0.81 (0.65–1.02)
106
58
37
All-cause mortality <0.006
0.006–<0.018
0.018
6.9
10.6
14.7
5.7
8.1
13.2
0.74 (0.58–0.94)
0.68 (0.54–0.86)
0.84 (0.69–1.01)
63
42
31
*Test for interaction not signiﬁcant for any category. Hazard ratios and 95% CI were adjusted for baseline troponin I (TnI) levels and for treatment, sex, stroke,
diabetes, smoking, hypertension, total cholesterol, apolipoprotein B, apolipoprotein A1, HDL cholesterol, age, nature of prior acute coronary syndromes,
timing of coronary revascularization, systolic BP, atrial ﬁbrillation, eGFR, body mass index, dyspnea class, angina grade, WBC count, peripheral vascular
disease, triglycerides, fasting glucose, and aspirin at baseline.
CHD ¼ coronary heart disease; CVD ¼ cardiovascular disease; NNT ¼ number needed to treat; other abbreviations as in Table 1.
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350The NRI with TnI was the second largest, before age and
after history of MI (Online Table 1).
Discussion
This study shows that baseline TnI levels measured with
a contemporary sensitive assay (5,14) are predictive of the
pre-speciﬁed combined endpoint of CHD death and MI
(highest tertile compared with lowest 64%) in patients who
were stable following a previous MI or unstable angina.
The contemporary sensitive TnI used in this study has
a coefﬁcient variation of 10% <99th percentile and has been
reported to detect troponin levels in 46.6% of a healthy
population (15). In the current study, levels of TnI were
detected in 62.3% of patients. Baseline TnI levels were also
predictive of an increase in a number of other events,
including MI (23% increase), stroke (39% increase), heart
failure (240% increase), and all-cause mortality (74%
increase). The effect of elevated baseline TnI levels appeared
to be greater on fatal than nonfatal CVD events.
Another novel ﬁnding was that changes in levels over the
ﬁrst year were predictors of CHD death and MI. Changes
were also related to all-cause mortality, with increased levels
being associated with increased mortality and decreases
being associated with decreased mortality.
The small effect of pravastatin on troponin levels was
statistically signiﬁcant but not clinically important.
Baseline troponin levels. The reasons for baseline
troponin elevations in patients with stable CHD may be
multiple (16), including subclinical ischemia, left ventricular
hypertrophy (LVH) (17,18), hypertension, diabetes (19),
atrial ﬁbrillation (20), or plaque rupture and microemboli
causing myocyte necrosis. Troponin levels may increase with
ischemia alone (16,21). It is therefore possible that theelevations of TnI levels may have been related to episodes of
repetitive ischemia.
Several studies have shown an association between hsTnT
levels and computed tomography angiography or invasive
angiographic severity of coronary artery disease in patients
with stable CHD (22,23). However, in one study, there was
no correlation with levels of hsTnT and extent of angio-
graphic disease, but there was a correlation with calcium
scoring and with the composition of coronary plaques as
assessed by computed tomography angiography (24). In
another study, patients with higher levels of hsTnT had
more noncalciﬁed coronary lesions, higher plaque volume,
and positively remodeled plaques, all features that have been
shown to correlate with risk of ACS (25,26).
It is well known that coronary artery plaque ruptures occur
frequently and that most are silent (27). Therefore, the
occurrence of plaque rupture and microemboli causing
myocyte necrosis may explain increased levels of troponin in
some patients at baseline and the association with nonfatal
MI.
However, our ﬁnding that the association of TnI levels
with nonfatal MI was weaker than for heart failure suggests
that the association may be more related to structural heart
disease than plaque rupture. This is supported by the
PEACE (Prevention of Events With Angiotensin Con-
verting Enzyme Inhibition) trial in patients with stable
CHD (55% of whom had previous MI) and normal systolic
function, in which elevated levels of hsTnT (>1 ng/l) had
a strong and graded association with the risk of both CVD
and heart failure but not MI (4).
Changes in troponin levels. TnI levels changed in
approximately 50% of patients over 1 year. Changes in TnI
moving from one tertile to another were related to increases
in the number of events, including hospitalization for heart
Figure 2
Forest Plots Showing Outcomes Related to Change in Troponin Levels According to Tertile Increase or Decrease,
Adjusted for 23 Baseline Variables and Baseline Troponin Tertile Category
HRs were compared with no change in TnI groups. *p value for trend. yHRs and 95% CI were adjusted for baseline TnI levels and for treatment, sex, stroke, diabetes, smoking,
hypertension, total cholesterol, ApoB, ApoA1, high-density lipoprotein cholesterol, age, nature of prior acute coronary syndrome, timing of coronary revascularization, systolic
blood pressure, atrial ﬁbrillation, estimated glomerular ﬁltration rate, body mass index, dyspnea class, angina grade, white blood cell count, peripheral vascular disease,
triglycerides, fasting glucose, and aspirin at baseline. Abbreviations as in Figure 1.
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351failure, unstable angina, coronary revascularization, and
mortality. For nonfatal MI, both decreases and increases in
TnI levels were associated with higher HRs and the p value
for trend was nonsigniﬁcant (p ¼ 0.32). The ﬁndings were
similar with change criteria of 50%.
Previous studies have reported an association between
increases in troponin levels and adverse outcomes in patients
with chest pain (28), with heart failure (29) and in an
elderly community population (3). Several studies have also
reported that decreases in troponin levels are associated with
decreases in number of events (3,30,31).
Our ﬁndings of changes in troponin levels over 1 year
have plausible potential explanations. Increases in troponin
levels over time could relate to ongoing myocyte necrosisrelated to the original MI; however, this is unlikely because
patients were enrolled for a minimum of 3 months to 3 years
after the index event and increases in troponin levels are
more likely due to chronic processes related to LVH (17,18),
increasing renal dysfunction, exacerbation of airway disease
(31), or poor diabetes control (19). Increases in troponin
levels could also relate to new events such as the develop-
ment of atrial ﬁbrillation (20), or plaque rupture, which is
supported by our ﬁndings of an association with unstable
angina and revascularization but not with our ﬁnding of no
association with MI.
Decreases in troponin levels could relate to decreases in
LVH related to better hypertension treatment, improvement
in renal function or diabetes control, or other risk factor
Figure 3 Landmark Models With 50% Change Criteria
*p value for trend. yHRs and 95% CI were adjusted for baseline TnI levels and for treatment, sex, stroke, diabetes, smoking, hypertension, total cholesterol, ApoB, ApoA1,
high-density lipoprotein cholesterol, age, nature of prior acute coronary syndrome, timing of coronary revascularization, systolic blood pressure, atrial ﬁbrillation, estimated
glomerular ﬁltration rate, body mass index, dyspnea class, angina grade, white blood cell count, peripheral vascular disease, triglycerides, fasting glucose, and aspirin at
baseline. Abbreviations as in Figure 1.
White et al. JACC Vol. 63, No. 4, 2014
1-Year Change in Sensitive Troponin I and Coronary Events February 4, 2014:345–54
352inﬂuences (e.g., cessation of smoking) (4). Although some
changes in TnI levels may alter subsequent risk through such
mechanisms, these changes were not related to the effects of
pravastatin in lowering the number of CHD events.
Overall, troponin levels may identify patients at high
global cardiovascular risk because baseline levels predicted
CHD death, MI, heart failure, stroke, and total mortality.
Changes in troponin levels modiﬁed risk for these events
and were modestly associated with admission with unstable
angina and revascularization. It may be possible to tailor
therapy according to risk on the basis of troponin levels (e.g.,
intensive risk factor modiﬁcation).
Relationship with stroke. In the current study in patients
with stable CHD who were predominantly in sinus rhythm,
both baseline and changes in TnI levels were associated with
risk of stroke (p ¼ 0.07 using categories and p ¼ 0.02 using50% change criteria). This is consistent with the ﬁnding
in patients in the RE-LY (Randomized Evaluation of
Long-Term Anticoagulation Therapy) study (20) with atrial
ﬁbrillation that higher levels of TnI were associated with
higher rates of stroke.
Net reclassiﬁcation improvement. Adding TnI to the
baseline risk model resulted in a modest improvement in the
NRI of 4.8%. Although the change in NRI appears small, it
was larger than that for age. Also, TnI levels added to the
LIPID risk model remained an independent predictor of
CHD death and MI after the addition of BNP and hsCRP.
This suggests that these biomarkers are related to different
mechanisms and carry different prognostic information in
stable patients after MI or unstable angina. Furthermore,
TnI level remained statistically signiﬁcant for a range of
clinical outcomes. This illustrates that TnI is important in
Table 5 Baseline and Landmark NRI, C-Statistic, and IDI for the Endpoint of CHD Death and MI
NRI IDI C-statistic
NRI, % p Value IDI p Value Without Troponin With Troponin
Baseline
Troponin added 4.76 0.01 0.0035 <0.001 0.665 0.673
Landmark
Troponin added 1.38 0.48 0.0009 0.04 0.675 0.677
Based on the same endpoint probabilities: 7.5%, 7.5% to 10%, 10% to 15%, and >15%. Patients changed classiﬁcation if they moved between
these categories in these 2 models (with and without troponin). The model without troponin included treatment, sex, stroke, diabetes, smoking,
hypertension, total cholesterol, HDL cholesterol, age, nature of prior acute coronary syndrome, timing of coronary revascularization, systolic BP,
atrial ﬁbrillation, eGFR, body mass index, dyspnea class, angina grade, WBC count, peripheral vascular disease, triglycerides, fasting glucose, and
aspirin at baseline. For the landmark model, it also included baseline troponin level.
IDI ¼ integrated discrimination index; NRI ¼ net reclassiﬁcation involvement index; other abbreviation as in Tables 1, 2, and 3.
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353the pathophysiology and natural history of patients with
CHD.
Study limitations. Biomarkers were not measured in all
patients. Choice of approximate tertiles was pragmatic and
driven largely by the fact that one-third of values were not
detectable (<0.006) using this TnI assay. Two-thirds of the
troponin values analyzed (and the entire middle tertile) were
below the level of guideline-endorsed analytical precision for
this assay (8). However, any analytical noise because of
imprecision in that range would be expected to have weak-
ened the observed risk relationships (15). The categories
used in the NRI are new because this was a secondary
prevention population at higher risk of events.
The biological variability and analytical variation of
the contemporary sensitive TnI assay we used may have
inﬂuenced the ﬁndings related to change in TnI levels over
1 year. Also, it is possible that regression to the mean may
have affected changes in measurements over time. We pre-
speciﬁed the change criterion on the basis of tertiles. Our
ﬁndings were similar using 50% increase or decrease
criteria which would be expected to be greater than the
biological variability (8). We used a World Health Orga-
nization protocol deﬁnition for MI and not the universal
deﬁnition (32), which would have detected many more
MIs. In our multivariate analysis, we did not have sufﬁ-
cient data to include ejection fraction.
The LIPID study was conducted some years ago.
However, the cohort has ongoing major relevance to current
clinical management. The study was undertaken in patients
who were at least 3 months after their qualifying MI or
hospitalization for unstable angina. Therefore, subsequent
major developments in the acute management of ACS are
not pertinent. Indeed, there was very high background
usage of present evidence-based therapies for ongoing
prevention in randomized patients. Furthermore, patients
had a broad range of cholesterol levels, reﬂecting those in
usual clinical practice. The cohort is one of the most well
characterized in research trials in CHD. Vital status
was ascertained in all but 1 patient, and all major cardio-
vascular events, the endpoints in the present study, were
adjudicated.Conclusions
Baseline TnI levels were independent predictors of CHD
death and nonfatal MI, as well as mortality and a wide range
of other CVD events, including heart failure and stroke.
Increases in TnI levels from baseline to 1 year were associ-
ated with higher total mortality, and decreases were associ-
ated with decreased total mortality.
Pravastatin resulted in a slightly greater reduction in TnI
levels than placebo but did not account for any of the effects
of pravastatin in reducing the number of CVD events.
Further research is needed to determine whether measure-
ment of baseline levels and change in TnI could guide
therapy, for example, by prompting more intensive risk
factor modiﬁcation.
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